JP2021527130A5 - - Google Patents

Info

Publication number
JP2021527130A5
JP2021527130A5 JP2021518059A JP2021518059A JP2021527130A5 JP 2021527130 A5 JP2021527130 A5 JP 2021527130A5 JP 2021518059 A JP2021518059 A JP 2021518059A JP 2021518059 A JP2021518059 A JP 2021518059A JP 2021527130 A5 JP2021527130 A5 JP 2021527130A5
Authority
JP
Japan
Prior art keywords
composition according
iodide
subject
disease
injury
Prior art date
Application number
JP2021518059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527130A (ja
JPWO2019237065A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036154 external-priority patent/WO2019237065A1/en
Publication of JP2021527130A publication Critical patent/JP2021527130A/ja
Publication of JP2021527130A5 publication Critical patent/JP2021527130A5/ja
Publication of JPWO2019237065A5 publication Critical patent/JPWO2019237065A5/ja
Pending legal-status Critical Current

Links

JP2021518059A 2018-06-08 2019-06-07 組織傷害および集中治療後症候群の処置および予防のためのハロゲン化合物の使用 Pending JP2021527130A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862682574P 2018-06-08 2018-06-08
US62/682,574 2018-06-08
US201862730927P 2018-09-13 2018-09-13
US201862730945P 2018-09-13 2018-09-13
US62/730,945 2018-09-13
US62/730,927 2018-09-13
PCT/US2019/036154 WO2019237065A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Publications (3)

Publication Number Publication Date
JP2021527130A JP2021527130A (ja) 2021-10-11
JP2021527130A5 true JP2021527130A5 (https=) 2022-05-13
JPWO2019237065A5 JPWO2019237065A5 (https=) 2022-05-13

Family

ID=68770655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518059A Pending JP2021527130A (ja) 2018-06-08 2019-06-07 組織傷害および集中治療後症候群の処置および予防のためのハロゲン化合物の使用

Country Status (10)

Country Link
US (1) US20210252047A1 (https=)
EP (1) EP3801565A4 (https=)
JP (1) JP2021527130A (https=)
KR (1) KR20210018898A (https=)
CN (1) CN112469422A (https=)
AU (1) AU2019282820A1 (https=)
CA (1) CA3102792A1 (https=)
IL (1) IL279221A (https=)
MX (1) MX2020013306A (https=)
WO (1) WO2019237065A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CZ295765B6 (cs) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Léčebný přípravek s virucidním účinkem
GB0525504D0 (en) * 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
MX386702B (es) * 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Similar Documents

Publication Publication Date Title
JP2014533733A5 (https=)
JP2014502641A5 (https=)
JP2016539164A5 (https=)
JP2011522876A (ja) 永続性心房細動を予防するためのドロネダロン
JP2019517542A5 (https=)
HRP20220058T1 (hr) Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja
JP2019533660A5 (https=)
JP2016510326A5 (https=)
Hwang et al. Extracorporeal membrane oxygenation for acute life-threatening neurogenic pulmonary edema following rupture of an intracranial aneurysm
US20210283049A1 (en) Intravenous sotalol hydrochloride loading and maintenance for cardiac surgery patients
US20230255908A1 (en) Methods of intravenously administering sotalol hydrochloride
US20230248674A1 (en) Methods of intravenously administering sotalol hydrochloride
US20230372268A1 (en) Methods of intravenously administering sotalol
TW201416095A (zh) 包含格米列汀與美氟明的組合藥物及其製備方法
JP2021527130A5 (https=)
JP2020527138A5 (https=)
KR102752382B1 (ko) 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
JP2018502924A5 (https=)
JP2016510040A5 (https=)
US20230241078A1 (en) Vanadyl and vanadate for use in reducing stress-induced metabolic derangement
JP2021532165A5 (https=)
JPWO2019237065A5 (https=)
Franco et al. Oral management of Steinert's disease and role of anxiolysis
Stefanescu et al. The management of post-tonsillectomy morbidity in patients with sleep apnoea
Park Multiple Angiodysplasia in the Stomach